Analyst consensus remains split, with targets ranging from $0.85 to $1. The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Amarin. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. Also, it’s worth noting that Pfizer’s comments at that same biotech conference didn’t indicate that a deal is coming soon. Pfizer’s CEO Albert Bourla noted that the company greatly stepped up its share buyback in 2018. It did so, Bourla said, in order to be able to boost R&D spending without hitting earnings. The amrn stock forecast for early 2024 suggests a potential upside if positive clinical data from ongoing trials materialize. Currently trading near $0.90, sentiment is mixed, with analysts watching FDA guidance closely. Trading volume spikes often precede speculative runs in biotech, making risk management key.
